Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZW) Common Equity (2020 - 2025)

Core Scientific (CORZW) has disclosed Common Equity for 6 consecutive years, with -$962.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 2.09% to -$962.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$962.7 million through Dec 2025, down 2.09% year-over-year, with the annual reading at -$962.7 million for FY2025, 2.09% down from the prior year.
  • Common Equity hit -$962.7 million in Q4 2025 for Core Scientific, up from -$1.3 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.3 billion in Q4 2021 to a low of -$1.3 billion in Q3 2025.
  • Historically, Common Equity has averaged -$305.1 million across 5 years, with a median of -$395.0 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 1403.19% in 2021 and later crashed 673.39% in 2023.
  • Year by year, Common Equity stood at $1.3 billion in 2021, then tumbled by 130.52% to -$409.3 million in 2022, then plummeted by 45.83% to -$596.9 million in 2023, then plummeted by 57.98% to -$943.0 million in 2024, then dropped by 2.09% to -$962.7 million in 2025.
  • Business Quant data shows Common Equity for CORZW at -$962.7 million in Q4 2025, -$1.3 billion in Q3 2025, and -$1.2 billion in Q2 2025.